VereDWDrug adverse reactions as masquereders. Adverse Drug Reaction Bull.1976;60:208–211.
2.
AhmedMDavisonOWSevere cystitis associated with tiaprofenic acid. Br Med J.1991;303:1376.
3.
GhoseK.Cystitis and nonsteroidal antiinflammatory drugs: an incidental association or an adverse effect?New Zealand Med J.1993;106:501–503.
4.
GreeneGFMillardOHNormanRWBoudreauSFAuldRBAwadSACystitis associated with tiaprofenic acid. J Urol.1994;152:1101–1102.
5.
HarrisonWJWillisRGNealDEAdverse reactions to tiaprofenic acid mimicking interstitial cystitis. Br Med J.1994;309:574.
6.
O'NeilGFTiaprofenic acid as a cause of non-bacterial cystitis. Med J Australia.1994;160:123–125.
7.
Anon. Severe cystitis with tiaprofenic acid (Surgam). Current Prob.1994;21:11.
8.
TerolMJCervantesFPereiraARozmanC.Autoimmune hemolytic anaemia after 9 years of treatment with alphmethyldopa. (letter). Med Clin Barc.1991;101:598.
9.
McKenzieRFriedMWSallieRConjeevaramHDi-BisceglieAMParkYSavareseBKleinerDTsokosMLucianoCHepatic failure and lactic acidosis due to fialuridine (FLAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med.1995;333(17):1099–1105.
10.
PepysJPepysEOBaldoBAWhitwamJGAnaphylactic/anaphylactoid reactions to anaesthetic and associated agents. Skin prick tests in aetiological diagnosis. Anaesthetic.1994;49:470–475.
11.
StephensM.Deliberate drug rechallenge. Hum Toxicol.1983;2(4):573–577.
MirosMKerlinPWalkerNHarrisO.Flucloxacillin induced delayed cholestatic hepatitis. Aust New Zealand J Med.1990;20:251–253.
14.
DaviesMHHarrisonRFEliasEHubscherSGAntibiotic-associated acute vanishing bile duct syndrome; a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol.1994;20:112–116.
15.
RawlinsMDPharmacovigilance: paradise lost, regained or postponed?J Roy Coll Physicians.1995;29:41–49.
16.
BatemanDNSandersGLSRawlinsMDAttitudes to adverse drug reaction reporting: The Northern Region. Br J Clin Pharmac.1992;34:421–426.
17.
HoughtonJEPinto PereiraLMWoodsFJRichensARoutledgePAThe Welsh Adverse Drug Reactions Scheme; experience of a UK regional monitoring centre. Adverse Drug Reac Toxicol Rev.1996;15(2).
18.
AlbengresEGauthierFTillementJPCurrent French system of post-marketing drug surveillance. Int J Clin Pharmacol Ther Toxicol.1990;312–314.
19.
BegaudBChaslerieAHaramburuF.Organization and results of drug vigilance in France. Rev Epidemiol Sante Publique.1994;42:416–423.
20.
EdwardsIRLindquistMWiholmBENapkeE.Quality criteria for early signals of possible adverse drug reactions. Lancet.1990;336:156–158.
21.
GriffinJPSurvey of the adverse drug reporting ode-mas in fifteen countries. Br J Clin Pharmacol.1986;22:835–1005.
22.
WalkerRSLintonALPhenethyldiguanide: A dangerous side-effect. Br Med J.1959;2:1005–1006.
23.
ChandaliaHBRangnathM.Biguanide induced lactic acidosis. J Ass Physicians India.1990;38:620–622.
24.
McGuinnessMETalbertRJPhenformin-induced lactic acidosis: a forgotten adverse drug reaction. Ann Pharmacother.1993;27:1183–1187.
25.
Soria-RoyerCLegendreCMirchevaJPremelSBeaunePKreisH.Thiopurine-methyl transferase activity to assess azathioprine myeltoxicity in renal transplant recipients (letter). Lancet.1993;341(8860) 1593–1594.
26.
EvansDAPManleyKAMakusickVAGenetic control of isoniazid metabolism in man. Br Med J.1960;2:485–491.
27.
AdamsLEHessEVDrug-related lupus. Incidence, mechanisms and clinical implications. Drug Safety.1991;6:431–449.
28.
HutchingsARoutledgePAA simple method for determining acetylator phenotype using isoniazid. Br J Clin Pharmac.1986;22:343–345.
29.
HutchingsARoutledgePAA single sample saliva test to measure acetylator phenotype using isoniazid. Br J Clin Pharmac.1996;42:635–637.
30.
BechtelPRRelevance and limits of pharmacogenetics to detect patients at risk of adverse drug reactions. Pharmacoepidem Drug Safety.1995;4:31–36.
